Barely Significant
← all excerpts

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States.

J Pediatr Gastroenterol Nutr · 2026 · PMC13150796 · PMID 41693511

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

marginally significantp = 0.06so close (0.05 < p ≤ 0.1)
However, linear contrasts revealed only a marginally significant difference between baseline and 8–12 weeks for albumin ( p = 0.06), with no significant differences between other specific time points (Figure 2 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.